JP2025509242A5 - - Google Patents
Info
- Publication number
- JP2025509242A5 JP2025509242A5 JP2024553192A JP2024553192A JP2025509242A5 JP 2025509242 A5 JP2025509242 A5 JP 2025509242A5 JP 2024553192 A JP2024553192 A JP 2024553192A JP 2024553192 A JP2024553192 A JP 2024553192A JP 2025509242 A5 JP2025509242 A5 JP 2025509242A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- seq
- gna11
- gnaqc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2203164.5 | 2022-03-07 | ||
| GBGB2203164.5A GB202203164D0 (en) | 2022-03-07 | 2022-03-07 | Methods of treatment of gnaq and gna11 mosaicism |
| GBGB2203233.8A GB202203233D0 (en) | 2022-03-08 | 2022-03-08 | Methods of treatment of GNAQ and GNA11 driven disease |
| GB2203233.8 | 2022-03-08 | ||
| PCT/EP2023/055817 WO2023170109A1 (en) | 2022-03-07 | 2023-03-07 | Methods of treatment of gnaq and gna11 driven disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509242A JP2025509242A (ja) | 2025-04-11 |
| JP2025509242A5 true JP2025509242A5 (https=) | 2026-03-16 |
Family
ID=85556425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553192A Pending JP2025509242A (ja) | 2022-03-07 | 2023-03-07 | Ｇｎａｑ及びｇｎａ１１駆動疾患の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250230435A1 (https=) |
| EP (1) | EP4490290A1 (https=) |
| JP (1) | JP2025509242A (https=) |
| AU (1) | AU2023232895A1 (https=) |
| WO (1) | WO2023170109A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025245193A1 (en) * | 2024-05-21 | 2025-11-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for inhibition of mutant gnaq and gna11 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2746514C (en) * | 2008-12-10 | 2018-11-27 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
| US10544461B2 (en) * | 2013-04-16 | 2020-01-28 | The Johns Hopkins University | Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (PWSS) |
| CN105218668B (zh) * | 2015-10-30 | 2020-03-24 | 山东农业大学 | 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用 |
| US20210403864A1 (en) * | 2018-11-06 | 2021-12-30 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treating activated g-alpha q mutant cancers or melanocytic malignancies |
-
2023
- 2023-03-07 JP JP2024553192A patent/JP2025509242A/ja active Pending
- 2023-03-07 EP EP23710004.5A patent/EP4490290A1/en active Pending
- 2023-03-07 AU AU2023232895A patent/AU2023232895A1/en active Pending
- 2023-03-07 WO PCT/EP2023/055817 patent/WO2023170109A1/en not_active Ceased
- 2023-03-07 US US18/844,507 patent/US20250230435A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| TWI784934B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| JP2021533804A5 (https=) | ||
| JPH09510714A (ja) | オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
| CA2808233A1 (en) | Aptamers to 4-1bb and their use in treating diseases and disorders | |
| JP2023500661A5 (https=) | ||
| CN118048356A (zh) | 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染 | |
| TW202305135A (zh) | 用於抑制己酮醣激酶（khk）之組合物及方法 | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| JP2011524745A (ja) | 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害 | |
| WO2023081500A2 (en) | RNAi OLIGONUCLEOTIDE CONJUGATES | |
| JP2021511072A5 (https=) | ||
| JP2025509242A5 (https=) | ||
| WO2025157271A1 (zh) | 一种抑制f11基因表达的核酸分子 | |
| JP2026500220A (ja) | 高度ｒｎａ標的化（ａｒｎａｔａｒ） | |
| WO2023134705A1 (zh) | 抑制angptl3表达的rna干扰剂及其用途 | |
| JP2026002846A (ja) | Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用 | |
| JP2022530678A5 (https=) | ||
| US20250066779A1 (en) | Advanced rna targeting (arnatar) for angiotensinogen | |
| JP2023528016A5 (https=) | ||
| JP2023528755A5 (https=) | ||
| WO2025103391A1 (zh) | 用于抑制lpa的基因表达的sirna，含其的组合物及其用途 | |
| US20230416743A1 (en) | Compositions and methods for inhibiting snca expression | |
| CN119452087A (zh) | 用于抑制乙型肝炎病毒的双链核糖核酸 | |
| CN114829601A (zh) | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 |